Image Source: AsiaOne
Late-breaking Results Show Efficacy for CCM in Patients With HFpEFInvestigators Report Positive Findings From Feasibility Study of CCM in Heart Failure With Preserved Ejection Fraction at the European Society of Cardiology Heart Failure 2022 CongressGlobeNewswireMay 23, 2022MADRID and MARLTON, N.J., May 23, 2022 (GLOBE NEWSWIRE) -- Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today a late-breaking presentation of results from the CCM-HFpEF Piloty Study, which is the largest clinical trial to date studying the effects of the company’s proprietary CCM® therapy to treat HF with preserved ejection fraction (HFpEF).
Source: AsiaOne